ClinicalTrials.gg
CompletedNCT01658878CheckMate040Updated Dec 24, 2025Results posted

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

A Phase 1/2 interventional study of Nivolumab and Sorafenib in Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 60 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
657
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.

Enrollment
5th of 53
657 · median 40
Started
2012
the only one that year
Phase 1/2
6 of 53
1 open now
Registered
1st of 53
by date
Lead sponsor
5 of 53
Bristol-Myers Squibb

Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 6 in phase 1/2, and was the 1st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing nivolumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus (HCV)-infected HCC subjects, and hepatitis B virus (HBV)-infected subjects).

The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses for each of the 3 cohorts. A third cohort has been added in this study to compare the efficacy of nivolumab and sorafenib in the treatment of Advanced HCC. A fourth cohort will generate data on the safety and efficacy of the combination nivolumab plus ipilimumab in the treatment of Advanced HCC. In the fifth cohort, additional clinical data will be generated for Child-Pugh B subjects. A Cabozantinib Combination Cohort has been added to evaluate the safety and tolerability of nivolumab in combination with cabozantinib and nivolumab with ipilimumab in combination with cabozantinib.

Read the detailed description

Study Classification: Pharmacokinetics/Pharmacodynamics

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Subjects of 18 years or older (men and women) with confirmed advanced hepatocellular carcinoma, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and /or locoregional therapies
  • (ECOG) Performance Status of 0 to 1
  • Dose Escalation Phase: score of 7 points or less. Cohort 5: Child-Pugh Class B (B7-B8). For all other cohorts Child-Pugh score of 6 points or less

Exclusion criteria

Exclusion Criteria:

  • History of disease
  • Any prior or current ascites
  • Any history of hepatic encephalopathy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
657 participants (actual)

Study arms

  • Experimental
    Non-infected: Nivolumab

    Nivolumab intravenous solution on specific days

    Biological: Nivolumab

  • Experimental
    HCV-infected: Nivolumab

    Nivolumab intravenous solution on specific days

    Biological: Nivolumab

  • Experimental
    HBV-infected: Nivolumab

    Nivolumab intravenous solution on specific days

    Biological: Nivolumab

  • Experimental
    Nivolumab

    Nivolumab intravenous solution on specific days

    Biological: Nivolumab

  • Active comparator
    Sorafenib

    Sorafenib tablets on specific days

    Drug: Sorafenib

  • Experimental
    Nivolumab plus Ipilimumab Combination

    Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days

    Biological: Nivolumab · Drug: Ipilimumab

  • Experimental
    Child-Pugh B

    Nivolumab intravenous solution on specific days

    Biological: Nivolumab

  • Experimental
    Nivolumab plus Cabozantinib Combination

    Nivolumab intravenous solution + cabozantinib oral tablets on specific days

    Drug: Cabozantinib

  • Experimental
    Nivolumab plus Ipilimumab plus Cabozantinib

    Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days

    Drug: Cabozantinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

  2. Number of Participants With Serious Adverse Events (SAEs)

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

  3. Number of Participants With Adverse Events Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

  4. Number of Participants Who Died

    Number of participants who died during the study.

    Time frame: From first dose of study medication until study closure (Up to approximately 144 months)

  5. Number of Participants With Laboratory Abnormalities in Specific Liver Tests

    Participants with abnormalities in liver function tests related to potential drug-induced liver injury. Blood samples were collected and analyzed for liver function parameters, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Abnormalities were assessed relative to the upper limit of normal (ULN) for each parameter. Abbreviations: ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal.

    Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

  6. Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

    Number of participants with thyroid-related laboratory abnormalities during the study. Blood samples were collected and analyzed for thyroid function markers (FT3, FT4). Abnormalities were assessed against LLN and ULN for each parameter. Abbreviations: FT3 = Free T3; FT4 = Free T4; LLN = Lower Limit of Normal; ULN = Upper Limit of Normal; TSH = Thyroid Stimulating Hormone

    Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

  7. Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 2

    Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

    Time frame: From the start of the study treatment until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)

  8. Objective Response Rate (ORR) by Investigator for Cohorts 3, 4, 5, and 6

    Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

    Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 5) until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)

Secondary outcomes

  1. Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 1

    Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

    Time frame: From the start of the study treatment until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)

  2. Number of Participants With Complete Response (CR) Assessed by Blinded Independent Central Review (BICR)

    The number of participants whose best overall response (BOR) is CR in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

    Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to approximately 144 months after first dose

  3. Disease Control Rate (DCR) Assessed by Blinded Independent Central Review (BICR)

    The percentage of participants whose best overall response (BOR) is CR, PR or SD in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Failure to meet criteria for complete or partial response, in the absence of progressive disease. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

    Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)

  4. Duration of Response (DOR) Assessed by Blinded Independent Central Review (BICR)

    DOR is defined as the time from the first documented objective response (either complete or partial response) until the date of disease progression or death from any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

    Time frame: From first documented response to first documented progression or death, whichever occurs first (Up to approximately 144 months)

  5. Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR)

    Time to Response (TTR) defined as the time from randomization to the date of the first confirmed CR or PR for Cohort 3, 4 and 6, and from the first dosing date of study medication to the date of the first confirmed CR or PR for cohort 1, 2 and 5. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) to the date of attainment of complete response (CR) or partial response (PR) (up to approximately 144 months)

  6. Time to Progression (TTP) Assessed by Blinded Independent Central Review (BICR)

    Time to Progression (TTP) is defined from the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) to the date of the first objectively documented disease progression. Participants who have not progressed as assessed by radiography will be censored at the last tumor assessment date prior to subsequent anti-cancer therapy. Participants who have no on-study tumor assessments were censored at the date of randomization. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

    Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)

  7. Time to Progression (TTP) Rate Assessed by Blinded Independent Central Review (BICR)

    TTP rate is defined as the percentage of participants without disease progression at select time points (milestones) during the study. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

    Time frame: At 6 and 12 months

  8. Progression Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR)

    PFS is defined as the time from randomization date or first dosing date of study medication to the date of the first objectively documented tumor progression or death due to any cause. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last tumor assessment. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

    Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to documented disease progression or death, whichever occurs first (up to approximately 144 months)

  9. Overall Survival (OS)

    OS is defined as the time from randomization date or first dosing date of study medication to the date of death (due to any cause). Participants who were alive were censored at the last known alive dates.

    Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to the date of death or date last known alive (up to approximately 144 months)

  10. Overall Survival (OS) Rate

    OS rate is defined as the percentage of participants who are still alive at certain time points during the study.

    Time frame: At 6, 12, 24, 48 and 60 months

  11. Maximum Observed Serum Concentration (Cmax)

    Cmax is the maximum observed serum concentration.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)

  12. Time of Maximum Observed Serum Concentration (Tmax)

    Tmax is the time taken to reach the maximum observed serum concentration (Cmax).

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)

  13. Area Under the Serum Concentration Time Curve in the Dosing Interval [AUC(TAU)]

    AUC (TAU) is the area measured under the concentration-time curve taken over the dosing interval.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)

  14. Serum Concentration Achieved at the End of Dosing Interval (Trough Concentration) (Ctrough)

    Ctrough is the lowest observed serum concentration.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)

  15. Serum Concentration Achieved at the End of the Infusion (Ceoinf)

    Serum Concentration Achieved at the End of the Infusion (Ceoinf) refers to the amount of drug present in the blood (serum) immediately after the completion of an infusion. It represents the concentration measured at the exact time the infusion ends, before any significant elimination or distribution occurs.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)

  16. Ratio of an Exposure Measure at Steady State to That After the First Dose (Exposure Measure Includes Cmax) (AI_Cmax)

    AI\_Cmax is ratio of an exposure measure at steady state to that after the first dose (exposure measure includes Cmax)

    Time frame: At Cycle 3 Day 1 (Each Cycle = 2 Weeks)

  17. Accumulation Index Ratio of AUC at Steady State to That After the First Dose (AI_AUC)

    AI\_AUC is accumulation index ratio of AUC at steady state to that after the first dose

    Time frame: At Cycle 3 Day 1 (Each Cycle = 2 Weeks)

  18. Effective T-Half (T-HALF)

    Effective half-life is defined as the time it takes for the amount of a drug in the body to decrease by half.

    Time frame: At Cycle 3 Day 1 (Each Cycle = 2 Weeks)

  19. Number of Participants With Anti-drug Antibodies (ADA)

    Baseline ADA Positive: Participant with baseline ADA-positive sample ADA Positive: Participant with at least one ADA-positive sample relative to baseline Persistent Positive (PP): ADA-positive sample at 2 or more consecutive timepoints Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling timepoint Other Positive: Not persistent but some ADA-positive samples with the last sample being negative ADA Negative: Participant with no ADA-positive sample after initiation of treatment

    Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

07

Results

Posted Dec 24, 2025

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestoneCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Started1333133435334565750516166504949493635
Randomized0000000000000000616650494903635
Completed1333133435334565750516062494948493635
Not completed000000000000000014101000
Treatment Period
Participant flow — Treatment Period
MilestoneCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Started1333133435334565750516062494948493635
Completed000000000000000000000000
Not completed1333133435334565750516062494948493635
Withdrew: Disease progression1321133435334434833464142283737392719
Withdrew: Study drug toxicity00010000000071505101242326
Withdrew: Maximum clinical benefit001000000000000000110000
Withdrew: Other reasons000100000000200211314004
Withdrew: Participant no longer meets study criteria000000000000001001000000
Withdrew: Poor/non-compliance000000000000000100000000
Withdrew: Participant withdrew consent000000000000102002121022
Withdrew: Participant request to discontinue study treatment000000000000243212011201
Withdrew: Adverse event related to study drug000000000000046000000000
Withdrew: Death000000000000100011000200
Withdrew: Adverse event0000000000000000103323343
Withdrew: Lost to follow-up000000000000000010110010

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Number of Participants With Adverse Events (AEs)1333133435334565650515859484748473635
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Number of Participants With Serious Adverse Events (SAEs)012050315302342829212725302729311721
PrimaryNumber of Participants With Adverse Events Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Discontinuation
ParticipantsCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Number of Participants With Adverse Events Leading to Discontinuation000110000100481031416167108712
PrimaryNumber of Participants Who Died

Number of participants who died during the study.

Time frame:
From first dose of study medication until study closure (Up to approximately 144 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Number of Participants Who Died1322131435334495240455253354140482926
PrimaryNumber of Participants With Laboratory Abnormalities in Specific Liver Tests

Participants with abnormalities in liver function tests related to potential drug-induced liver injury. Blood samples were collected and analyzed for liver function parameters, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Abnormalities were assessed relative to the upper limit of normal (ULN) for each parameter. Abbreviations: ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal.

Time frame:
From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
ParticipantsCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
ALT or AST > 3 X Upper limit of Normal (ULN)011172412022222032122321292523272321
Alanine Transaminase (ALT) OR AST > 5 X ULN011102212021101022597221411171219
ALT or Aspartate Transaminase (AST) > 10 X ULN0000000000214510432877259
ALT or AST > 15 X ULN000000000021233132232113
ALT or AST > 20 X ULN000000000010132121221102
Total Bilirubin > 2 X ULN00102010101159106131211921758
Total Bilirubin > 8 X ULN000010000000003030540101
Total Bilirubin >8XULN if Elevated at Entry Or >5XULN if Normal at Entry001010000000014130540201
Concurrent ALT OR AST Elevation > 3 X ULN with Total Bilirubin > 2 X ULN within One Day00102010101136759109711047
Concurrent ALT or AST elevation > 3 X ULN with Total Bilirubin > 2 X ULN within 30 Days00102010101136759119711147
Concurrent Alt>=10XULN & Total Bilirubin >=2XULN Or 2X Baseline if Elevated Total Bilirubin at Entry000000000000100121000001
PrimaryNumber of Participants With Laboratory Abnormalities in Specific Thyroid Tests

Number of participants with thyroid-related laboratory abnormalities during the study. Blood samples were collected and analyzed for thyroid function markers (FT3, FT4). Abnormalities were assessed against LLN and ULN for each parameter. Abbreviations: FT3 = Free T3; FT4 = Free T4; LLN = Lower Limit of Normal; ULN = Upper Limit of Normal; TSH = Thyroid Stimulating Hormone

Time frame:
From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
ParticipantsCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
TSH > ULN (Upper Limit of Normal)01115113010120232117151923151562117
TSH > ULN with TSH <= ULN at baseline0010310001001517131111151811952014
TSH > ULN with at least one FT3/FT4 test value < LLN (Lower Limit of Normal)00001012000171465661084367
TSH > ULN with all other FT3/FT4 test values >= LLN00002000010011814106911453116
TSH > ULN with FT3/FT4 test missing011121010000211234236044
TSH < LLN0000100020011078926161310569
TSH < LLN with TSH >= LLN at baseline00001000200167772415129549
TSH < LLN with at least one FT3/FT4 test value > ULN000000000000734112966225
TSH < LLN with all other FT3/FT4 test values <= ULN000000001001143814523134
TSH < LLN with FT3/FT4 test missing000010001000201000251210
PrimaryObjective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 2

Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time frame:
From the start of the study treatment until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Reported as:
Number · Percent of Participants
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 2
Percent of ParticipantsCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 219.6 (10.2 to 32.4)14.0 (6.3 to 25.8)20.0 (10.0 to 33.7)13.7 (5.7 to 26.3)
PrimaryObjective Response Rate (ORR) by Investigator for Cohorts 3, 4, 5, and 6

Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time frame:
From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 5) until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Reported as:
Number · Percent of Participants
Objective Response Rate (ORR) by Investigator for Cohorts 3, 4, 5, and 6
Percent of ParticipantsCohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Objective Response Rate (ORR) by Investigator for Cohorts 3, 4, 5, and 611.5 (4.7 to 22.2)4.5 (0.9 to 12.7)36.0 (22.9 to 50.8)26.5 (14.9 to 41.1)28.6 (16.6 to 43.3)12.2 (4.6 to 24.8)16.7 (6.4 to 32.8)25.7 (12.5 to 43.3)
SecondaryObjective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 1

Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time frame:
From the start of the study treatment until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Reported as:
Number · Percent of Participants
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 1
Percent of ParticipantsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 113.0 (2.8 to 33.6)20.0 (2.5 to 55.6)13.3 (1.7 to 40.5)
SecondaryNumber of Participants With Complete Response (CR) Assessed by Blinded Independent Central Review (BICR)

The number of participants whose best overall response (BOR) is CR in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Time frame:
From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to approximately 144 months after first dose
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR) Assessed by Blinded Independent Central Review (BICR)
ParticipantsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Number of Participants With Complete Response (CR) Assessed by Blinded Independent Central Review (BICR)100202411441013
SecondaryDisease Control Rate (DCR) Assessed by Blinded Independent Central Review (BICR)

The percentage of participants whose best overall response (BOR) is CR, PR or SD in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Failure to meet criteria for complete or partial response, in the absence of progressive disease. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time frame:
From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Reported as:
Number · Percent of Participants
Disease Control Rate (DCR) Assessed by Blinded Independent Central Review (BICR)
Percent of ParticipantsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Disease Control Rate (DCR) Assessed by Blinded Independent Central Review (BICR)47.8 (26.8 to 69.4)70.0 (34.8 to 93.3)40.0 (16.3 to 67.7)66.1 (52.2 to 78.2)56.1 (42.4 to 69.3)54.0 (39.3 to 68.2)47.1 (32.9 to 61.5)52.5 (39.3 to 65.4)62.1 (49.3 to 73.8)54.0 (39.3 to 68.2)42.9 (28.8 to 57.8)49.0 (34.4 to 63.7)44.9 (30.7 to 59.8)77.8 (60.8 to 89.9)80.0 (63.1 to 91.6)
SecondaryDuration of Response (DOR) Assessed by Blinded Independent Central Review (BICR)

DOR is defined as the time from the first documented objective response (either complete or partial response) until the date of disease progression or death from any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time frame:
From first documented response to first documented progression or death, whichever occurs first (Up to approximately 144 months)
Reported as:
Median · Months
Duration of Response (DOR) Assessed by Blinded Independent Central Review (BICR)
MonthsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Duration of Response (DOR) Assessed by Blinded Independent Central Review (BICR)NA (8.74 to NA)12.55 (5.75 to NA)6.41 (2.83 to NA)22.57 (5.62 to 31.80)11.30 (5.55 to NA)NA (3.15 to NA)NA (8.31 to NA)5.21 (2.10 to NA)9.26 (5.45 to NA)17.48 (8.31 to 52.47)22.21 (9.36 to NA)16.59 (4.34 to 48.20)18.40 (NA to NA)21.55 (10.84 to NA)49.51 (7.72 to NA)
SecondaryTime to Response (TTR) Assessed by Blinded Independent Central Review (BICR)

Time to Response (TTR) defined as the time from randomization to the date of the first confirmed CR or PR for Cohort 3, 4 and 6, and from the first dosing date of study medication to the date of the first confirmed CR or PR for cohort 1, 2 and 5. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) to the date of attainment of complete response (CR) or partial response (PR) (up to approximately 144 months)
Reported as:
Median · Months
Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR)
MonthsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR)1.41 (1.4 to 2.8)3.15 (2.3 to 4.0)1.99 (1.3 to 2.7)2.73 (1.3 to 6.8)3.63 (2.6 to 5.7)2.78 (1.2 to 7.0)1.38 (1.2 to 6.8)3.50 (1.9 to 5.7)2.81 (1.9 to 5.5)2.00 (1.1 to 12.8)2.58 (1.2 to 5.5)2.66 (1.2 to 8.7)2.66 (1.4 to 4.2)5.13 (1.3 to 5.7)4.17 (1.3 to 8.1)
SecondaryTime to Progression (TTP) Assessed by Blinded Independent Central Review (BICR)

Time to Progression (TTP) is defined from the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) to the date of the first objectively documented disease progression. Participants who have not progressed as assessed by radiography will be censored at the last tumor assessment date prior to subsequent anti-cancer therapy. Participants who have no on-study tumor assessments were censored at the date of randomization. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time frame:
From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Reported as:
Median · Months
Time to Progression (TTP) Assessed by Blinded Independent Central Review (BICR)
MonthsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Time to Progression (TTP) Assessed by Blinded Independent Central Review (BICR)2.66 (1.38 to 4.21)8.21 (1.31 to NA)2.96 (1.25 to 6.97)4.01 (2.76 to 4.63)2.79 (1.48 to 5.59)3.94 (2.63 to 8.05)2.63 (1.38 to 4.04)4.83 (1.94 to 5.55)4.63 (3.32 to 12.94)4.27 (2.63 to 9.69)1.68 (1.35 to 13.90)2.73 (1.45 to 5.65)2.79 (1.41 to 5.36)5.42 (2.76 to 11.47)11.63 (4.11 to 36.86)
SecondaryTime to Progression (TTP) Rate Assessed by Blinded Independent Central Review (BICR)

TTP rate is defined as the percentage of participants without disease progression at select time points (milestones) during the study. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time frame:
At 6 and 12 months
Reported as:
Number · Percent of Participants
Time to Progression (TTP) Rate Assessed by Blinded Independent Central Review (BICR)
Percent of ParticipantsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
6 Months28.6 (11.7 to 48.2)60.0 (25.3 to 82.7)27.9 (7.1 to 54.1)33.9 (21.4 to 46.9)32.8 (20.2 to 46.0)41.5 (26.9 to 55.5)26.0 (14.7 to 38.9)30.1 (17.3 to 44.0)42.5 (27.2 to 56.9)42.5 (28.0 to 56.3)43.6 (28.7 to 57.5)32.4 (19.3 to 46.2)31.6 (16.9 to 47.4)42.8 (25.2 to 59.3)50.0 (30.3 to 66.9)
12 Months17.1 (4.6 to 36.5)24.0 (3.8 to 53.7)18.6 (3.0 to 44.5)21.4 (11.3 to 33.6)19.3 (9.0 to 32.4)30.9 (17.7 to 45.1)13.0 (5.3 to 24.2)12.2 (4.1 to 25.0)35.4 (20.5 to 50.6)33.1 (19.8 to 46.9)35.9 (21.9 to 50.1)27.6 (15.4 to 41.3)14.7 (4.4 to 31.0)32.1 (16.5 to 48.9)45.0 (25.5 to 62.7)
SecondaryProgression Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR)

PFS is defined as the time from randomization date or first dosing date of study medication to the date of the first objectively documented tumor progression or death due to any cause. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last tumor assessment. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time frame:
From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to documented disease progression or death, whichever occurs first (up to approximately 144 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR)
MonthsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Progression Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR)2.69 (1.38 to 4.21)8.97 (1.31 to 14.06)2.96 (1.25 to 4.07)4.01 (2.76 to 4.60)2.76 (1.48 to 4.40)3.94 (2.63 to 7.23)2.63 (1.35 to 4.04)3.78 (1.84 to 5.45)3.91 (3.32 to 5.65)3.91 (2.60 to 8.31)1.61 (1.35 to 6.93)2.63 (1.31 to 4.50)2.30 (1.41 to 3.42)5.13 (2.76 to 10.91)4.27 (3.58 to 11.86)
SecondaryOverall Survival (OS)

OS is defined as the time from randomization date or first dosing date of study medication to the date of death (due to any cause). Participants who were alive were censored at the last known alive dates.

Time frame:
From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to the date of death or date last known alive (up to approximately 144 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Overall Survival (OS)14.32 (5.65 to 18.14)36.27 (3.61 to 55.10)10.45 (3.68 to 20.21)26.68 (17.71 to 34.40)13.44 (8.57 to 18.89)17.45 (13.04 to 25.66)15.64 (9.69 to 20.67)15.24 (11.07 to 22.90)13.96 (8.71 to 19.25)22.24 (9.43 to 54.83)12.48 (7.62 to 16.39)12.75 (7.43 to 30.52)7.85 (4.37 to 10.51)20.21 (13.11 to 32.20)22.11 (15.15 to 36.50)
SecondaryOverall Survival (OS) Rate

OS rate is defined as the percentage of participants who are still alive at certain time points during the study.

Time frame:
At 6, 12, 24, 48 and 60 months
Reported as:
Number · Percent of Participants
Overall Survival (OS) Rate
Percent of ParticipantsCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV InfectedCohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
6 Months69.6 (46.6 to 84.2)80.0 (40.9 to 94.6)53.3 (26.3 to 74.4)89.0 (77.0 to 94.9)75.4 (62.1 to 84.7)83.3 (69.3 to 91.3)84.3 (71.1 to 91.8)81.3 (68.8 to 89.2)76.7 (63.8 to 85.5)81.7 (67.7 to 90.0)75.0 (60.2 to 85.0)73.5 (58.7 to 83.6)59.2 (44.2 to 71.4)82.4 (64.9 to 91.7)82.4 (65.0 to 91.7)
12 Months60.9 (38.3 to 77.4)80.0 (40.9 to 94.6)46.7 (21.2 to 68.7)76.0 (62.3 to 85.3)54.4 (40.7 to 66.2)67.5 (51.9 to 79.0)58.8 (44.1 to 70.9)57.1 (43.4 to 68.6)57.0 (43.2 to 68.6)60.7 (45.6 to 72.9)56.1 (41.0 to 68.8)50.8 (36.1 to 63.7)34.7 (21.8 to 47.9)70.2 (51.6 to 82.7)70.6 (52.3 to 83.0)
24 Months26.1 (10.6 to 44.7)60.0 (25.3 to 82.7)26.7 (8.3 to 49.6)57.0 (42.7 to 69.0)26.3 (15.7 to 38.1)38.9 (24.5 to 53.0)36.6 (23.6 to 49.7)32.9 (21.3 to 45.0)30.4 (18.8 to 42.8)46.1 (31.7 to 59.3)30.2 (17.9 to 43.5)42.3 (28.3 to 55.7)10.2 (3.7 to 20.5)39.0 (22.6 to 55.2)46.1 (28.7 to 61.8)
48 Months17.4 (5.4 to 35.0)30.0 (7.1 to 57.8)6.7 (0.4 to 26.0)20.9 (11.2 to 32.7)11.7 (4.9 to 21.7)14.6 (6.0 to 26.9)12.2 (5.0 to 22.9)15.6 (7.5 to 26.5)8.4 (2.7 to 18.0)37.0 (23.5 to 50.6)21.6 (11.2 to 34.2)25.4 (14.2 to 38.2)00 (00 to 00)19.0 (7.5 to 34.4)30.7 (16.1 to 46.6)
60 Months8.7 (1.5 to 24.2)15.0 (1.0 to 45.7)6.7 (0.4 to 26.0)15.2 (7.1 to 26.1)9.7 (3.7 to 19.3)14.6 (6.0 to 26.9)12.2 (5.0 to 22.9)8.9 (3.0 to 18.8)5.6 (1.2 to 15.1)29.6 (17.1 to 43.2)19.2 (9.4 to 31.6)21.2 (11.0 to 33.6)00 (00 to 00)15.2 (5.1 to 30.2)24.6 (11.6 to 40.0)
SecondaryMaximum Observed Serum Concentration (Cmax)

Cmax is the maximum observed serum concentration.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Reported as:
Geometric mean · ug/mL
Maximum Observed Serum Concentration (Cmax)
ug/mLCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Cycle 1 Day 160.06 ± 335.8719.81 ± 109.889.82 ± 244.81
Cycle 3 Day 1100.74 ± 339.2723.09 ± 130.6615.54 ± 379.81
SecondaryTime of Maximum Observed Serum Concentration (Tmax)

Tmax is the time taken to reach the maximum observed serum concentration (Cmax).

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Reported as:
Median · Hour
Time of Maximum Observed Serum Concentration (Tmax)
HourCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Cycle 1 Day 13.00 (1.0 to 25.2)2.98 (0.9 to 25.2)3.00 (0.9 to 23.9)
Cycle 3 Day 112.75 (0.9 to 24.3)12.28 (1.0 to 24.5)24.13 (0.8 to 25.7)
SecondaryArea Under the Serum Concentration Time Curve in the Dosing Interval [AUC(TAU)]

AUC (TAU) is the area measured under the concentration-time curve taken over the dosing interval.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Reported as:
Geometric mean · ug.h/mL
Area Under the Serum Concentration Time Curve in the Dosing Interval [AUC(TAU)]
ug.h/mLCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Cycle 1 Day 19114.43 ± 366.712825.09 ± 159.471313.76 ± 287.76
Cycle 3 Day 115229.27 ± 383.943358.78 ± 79.683731.16 ± 505.00
SecondarySerum Concentration Achieved at the End of Dosing Interval (Trough Concentration) (Ctrough)

Ctrough is the lowest observed serum concentration.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Reported as:
Geometric mean · ug/mL
Serum Concentration Achieved at the End of Dosing Interval (Trough Concentration) (Ctrough)
ug/mLCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Cycle 1 Day 116.52 ± 383.954.40 ± 194.652.26 ± 412.75
Cycle 3 Day 132.48 ± 430.866.76 ± 97.218.51 ± 473.58
SecondarySerum Concentration Achieved at the End of the Infusion (Ceoinf)

Serum Concentration Achieved at the End of the Infusion (Ceoinf) refers to the amount of drug present in the blood (serum) immediately after the completion of an infusion. It represents the concentration measured at the exact time the infusion ends, before any significant elimination or distribution occurs.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Reported as:
Geometric mean · ug/mL
Serum Concentration Achieved at the End of the Infusion (Ceoinf)
ug/mLCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Cycle 1 Day 149.88 ± 315.3917.07 ± 123.956.99 ± 254.53
Cycle 3 Day 184.36 ± 371.9225.53 ± 147.1611.80 ± 353.06
SecondaryRatio of an Exposure Measure at Steady State to That After the First Dose (Exposure Measure Includes Cmax) (AI_Cmax)

AI\_Cmax is ratio of an exposure measure at steady state to that after the first dose (exposure measure includes Cmax)

Time frame:
At Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Reported as:
Geometric mean · Ratio
Ratio of an Exposure Measure at Steady State to That After the First Dose (Exposure Measure Includes Cmax) (AI_Cmax)
RatioCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Ratio of an Exposure Measure at Steady State to That After the First Dose (Exposure Measure Includes Cmax) (AI_Cmax)2.26 ± 69.851.53 ± 23.341.45 ± 23.94
SecondaryAccumulation Index Ratio of AUC at Steady State to That After the First Dose (AI_AUC)

AI\_AUC is accumulation index ratio of AUC at steady state to that after the first dose

Time frame:
At Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Reported as:
Geometric mean · Ratio
Accumulation Index Ratio of AUC at Steady State to That After the First Dose (AI_AUC)
RatioCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Accumulation Index Ratio of AUC at Steady State to That After the First Dose (AI_AUC)2.60 ± 24.542.23 ± 9.802.28 ± 8.90
SecondaryEffective T-Half (T-HALF)

Effective half-life is defined as the time it takes for the amount of a drug in the body to decrease by half.

Time frame:
At Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Reported as:
Geometric mean · Hour
Effective T-Half (T-HALF)
HourCohort 1 Uninfected HCCCohort 1 HCV InfectedCohort 1 HBV Infected
Effective T-Half (T-HALF)468.07 ± 27.65382.36 ± 15.52406.60 ± 15.65
SecondaryNumber of Participants With Anti-drug Antibodies (ADA)

Baseline ADA Positive: Participant with baseline ADA-positive sample ADA Positive: Participant with at least one ADA-positive sample relative to baseline Persistent Positive (PP): ADA-positive sample at 2 or more consecutive timepoints Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling timepoint Other Positive: Not persistent but some ADA-positive samples with the last sample being negative ADA Negative: Participant with no ADA-positive sample after initiation of treatment

Time frame:
From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA)
ParticipantsCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4
Baseline ADA Positive00010000000010351
ADA Positive0220121011111819167
ADA Positive [Persistent Positive (PP)]0010000010002130
ADA Positive [Not PP-Last Sample Positive]0210101000104391
ADA Positive [Other Positive]000002000101121546
Neutralizing Positive0000000010000200
ADA Negative111311133422335352843

Adverse events

Collected over Participants were assessed for All-Cause Mortality from the date of their randomization (Cohorts 3, 4, and 6) or first dose (Cohorts 1, 2, and 5) until study completion (assessed up to approximately 144 months). SAEs and Other AEs were assessed from first dose of study medication through 100 days following last dose of study treatment (Assessed for approximately 04 months up to a max of approximately 106 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 Uninfected HCC: Treatment 11/1 (100%)0/1 (0%)1/1 (100%)
Cohort 1 Uninfected HCC: Treatment 23/3 (100%)1/3 (33.3%)3/3 (100%)
Cohort 1 Uninfected HCC: Treatment 32/3 (66.7%)2/3 (66.7%)3/3 (100%)
Cohort 1 Uninfected HCC: Treatment 42/3 (66.7%)0/3 (0%)3/3 (100%)
Cohort 1 Uninfected HCC: Treatment 513/13 (100%)8/13 (61.5%)13/13 (100%)
Cohort 1 HCV Infected: Treatment 61/3 (33.3%)0/3 (0%)3/3 (100%)
Cohort 1 HCV Infected: Treatment 74/4 (100%)3/4 (75%)4/4 (100%)
Cohort 1 HCV Infected: Treatment 83/3 (100%)1/3 (33.3%)3/3 (100%)
Cohort 1 HBV Infected: Treatment 95/5 (100%)5/5 (100%)5/5 (100%)
Cohort 1 HBV Infected: Treatment 103/3 (100%)3/3 (100%)3/3 (100%)
Cohort 1 HBV Infected: Treatment 113/3 (100%)1/3 (33.3%)3/3 (100%)
Cohort 1 HBV Infected: Treatment 124/4 (100%)3/4 (75%)4/4 (100%)
Cohort 2: Nivolumab 3 mg/kg186/214 (86.9%)137/214 (64%)210/214 (98.1%)
Cohort 3: Treatment 152/61 (85.2%)35/60 (58.3%)55/60 (91.7%)
Cohort 3: Treatment 253/66 (80.3%)33/62 (53.2%)57/62 (91.9%)
Cohort 4: Treatment 136/50 (72%)35/49 (71.4%)47/49 (95.9%)
Cohort 4: Treatment 241/49 (83.7%)36/49 (73.5%)47/49 (95.9%)
Cohort 4: Treatment 341/49 (83.7%)36/48 (75%)45/48 (93.8%)
Cohort 5: Treatment 148/49 (98%)37/49 (75.5%)42/49 (85.7%)
Cohort 6: Treatment 129/36 (80.6%)22/36 (61.1%)36/36 (100%)
Cohort 6: Treatment 226/35 (74.3%)25/35 (71.4%)35/35 (100%)
Most frequent serious events
Showing 10 of 302
Most frequent serious events
EventCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2: Nivolumab 3 mg/kgCohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/10/31/30/34/130/32/40/31/52/30/33/452/21410/6010/6212/4915/4918/4818/496/365/35
AscitesGastrointestinal disorders0/10/30/30/30/130/30/40/30/51/31/32/44/2141/606/622/491/493/483/490/360/35
AnaemiaBlood and lymphatic system disorders0/10/30/30/30/130/30/40/30/51/30/31/43/2140/600/623/493/492/481/491/360/35
Adrenal insufficiencyEndocrine disorders0/10/30/30/30/130/30/40/30/51/30/30/40/2142/601/622/490/490/480/490/361/35
Non-cardiac chest painGeneral disorders0/11/30/30/30/130/30/40/30/50/30/30/41/2140/600/620/490/490/480/490/360/35
PyrexiaGeneral disorders0/10/30/30/30/130/30/40/30/51/30/30/47/2142/600/624/493/494/480/493/360/35
HypoglycaemiaMetabolism and nutrition disorders0/10/31/30/30/130/30/40/31/50/30/31/41/2140/600/621/491/491/480/490/360/35
Neck painMusculoskeletal and connective tissue disorders0/10/31/30/30/130/30/40/30/50/30/30/40/2140/600/620/490/490/480/490/360/35
CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/10/31/30/30/130/30/40/30/50/30/30/40/2140/600/620/490/490/480/490/360/35
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/10/30/30/30/130/30/40/30/50/31/30/40/2140/600/620/490/490/480/490/360/35
Most frequent other events
Showing 10 of 237
Most frequent other events
EventCohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2: Nivolumab 3 mg/kgCohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2
AscitesGastrointestinal disorders1/10/30/30/31/130/31/40/30/51/30/33/422/2146/6010/628/496/498/4818/496/363/35
DiarrhoeaGastrointestinal disorders1/11/30/30/34/133/31/40/31/51/32/32/461/21411/6032/6219/4911/4919/489/4921/3615/35
VomitingGastrointestinal disorders1/10/30/30/33/130/30/40/31/50/30/31/437/2148/606/626/4910/497/480/495/367/35
Oedema peripheralGeneral disorders1/10/30/30/31/130/30/41/30/51/30/32/435/2148/607/6210/4911/4914/4813/494/367/35
Upper respiratory tract infectionInfections and infestations0/10/30/30/31/133/30/40/33/51/30/30/413/2142/601/621/496/492/482/492/362/35
Aspartate aminotransferase increasedInvestigations1/10/31/31/34/132/32/40/32/50/31/31/438/21410/6010/6217/4916/4911/486/4910/3615/35
Blood alkaline phosphatase increasedInvestigations1/10/31/30/31/130/30/40/32/50/30/31/412/2143/605/626/493/495/480/493/366/35
Decreased appetiteMetabolism and nutrition disorders1/10/30/30/34/130/33/40/32/52/32/33/457/21412/6022/6220/4913/4915/482/498/368/35
HyponatraemiaMetabolism and nutrition disorders1/10/32/31/32/131/33/41/30/50/30/31/47/2148/603/629/494/496/482/491/363/35
FatigueGeneral disorders0/11/30/31/35/131/33/40/32/51/30/31/486/21423/6021/6211/4911/4913/485/4910/3611/35

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2Total
<=18 years0000000000000000000000000
Between 18 and 65 years121292201233232825382433312436161816340
>=65 years012141234101332925133733192513331819317
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2Total
Female020131121010815812101071291045122
Male1132102314324484242395156433740393230535
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 Uninfected HCC: Treatment 1Cohort 1 Uninfected HCC: Treatment 2Cohort 1 Uninfected HCC: Treatment 3Cohort 1 Uninfected HCC: Treatment 4Cohort 1 Uninfected HCC: Treatment 5Cohort 1 HCV Infected: Treatment 6Cohort 1 HCV Infected: Treatment 7Cohort 1 HCV Infected: Treatment 8Cohort 1 HBV Infected: Treatment 9Cohort 1 HBV Infected: Treatment 10Cohort 1 HBV Infected: Treatment 11Cohort 1 HBV Infected: Treatment 12Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1Cohort 2 Uninfected Sorafenib Progressors: Treatment 2Cohort 2 HCV Infected: Treatment 3Cohort 2 HBV Infected: Treatment 4Cohort 3: Treatment 1Cohort 3: Treatment 2Cohort 4: Treatment 1Cohort 4: Treatment 2Cohort 4: Treatment 3Cohort 5: Treatment 1Cohort 6: Treatment 1Cohort 6: Treatment 2Total
White023311332100038342943942122015272623337
Black or African American01001000000011221211322121
Asian10001011433416221845192137273020810291
American Indian or Alaska Native0000000000000000000000000
Native Hawaiian or Other Pacific Islander0000000000001000000000001
Other0000000000000010210100016
Not Reported0000000000000000000010001
08

Study locations

60 sites
  • Local Institution - 0008
    Los Angeles, California 90033, United States
  • Local Institution - 0048
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0053
    Pensacola, Florida 32504, United States
  • Local Institution - 0047
    Atlanta, Georgia 30322, United States
  • Local Institution - 0025
    Boston, Massachusetts 02114, United States
  • Local Institution - 0002
    Ann Arbor, Michigan 48109-5331, United States
  • Local Institution - 0054
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0067
    Paterson, New Jersey 07503, United States
  • Local Institution - 0001
    Portland, Oregon 97213, United States
  • The University Of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Local Institution - 0065
    Halifax, Nova Scotia B4H 2Y9, Canada
  • Local Institution - 0039
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0022
    Montreal, Quebec H2X 3E4, Canada
  • Local Institution - 0061
    Angers, 49933, France
  • Local Institution - 0064
    Créteil, 94010, France
  • Local Institution - 0062
    Marseille, 13273, France
  • Local Institution - 0059
    Marseille, 13385, France
  • Local Institution - 0042
    Paris, 75651, France
  • Local Institution - 0060
    Reims, 51092, France
  • Local Institution - 0058
    Vandœuvre-lès-Nancy, 54500, France
  • Local Institution - 0030
    Essen, 45147, Germany
  • Local Institution - 0028
    Frankfurt, 60590, Germany
  • Local Institution - 0029
    Hanover, 30625, Germany
  • Local Institution - 0031
    Heidelberg, 69120, Germany
  • Local Institution - 0005
    Hong Kong, 0, Hong Kong
  • Local Institution - 0006
    Hong Kong, Hong Kong
  • Local Institution - 0032
    Bologna, 40138, Italy
  • Local Institution - 0056
    Florence, 50134, Italy
  • Local Institution - 0063
    Meldola (FC), 47014, Italy
  • Local Institution - 0055
    Milan, 20141, Italy
  • Local Institution - 0034
    Naples, 80131, Italy
  • Local Institution - 0035
    Padova, Padova, Italy
  • Local Institution - 0040
    Rozzano, 20089, Italy
  • Local Institution - 0036
    Kashiwa-shi, Chiba 2778577, Japan
  • Local Institution - 0038
    Kurume-shi, Fukuoka 8300011, Japan
  • Local Institution - 0049
    Yokohama, Kanagawa 2320024, Japan
  • Local Institution - 0050
    Kyoto, Kyoto 6028566, Japan
  • Local Institution - 0037
    Ōsaka-sayama, Osaka 5898511, Japan
  • Local Institution - 0051
    Saga, 8408571, Japan
  • Local Institution - 0070
    San Juan, 00927, Puerto Rico
  • Local Institution - 0017
    Singapore, 119074, Singapore
  • Local Institution - 0009
    Singapore, 168583, Singapore
  • Local Institution - 0007
    Singapore, 308433, Singapore
  • Local Institution - 0066
    Seoul, 02841, South Korea
  • Local Institution - 0021
    Seoul, 03080, South Korea
  • Local Institution - 0026
    Seoul, 05505, South Korea
  • Local Institution - 0016
    Seoul, 06351, South Korea
  • Local Institution - 0019
    Barcelona, 08036, Spain
  • Local Institution - 0020
    Madrid, 28009, Spain
  • Local Institution - 0018
    Madrid, 28050, Spain
  • Local Institution - 0003
    Pamplona, 31008, Spain
  • Local Institution - 0027
    Taipei, 100, Taiwan
  • Local Institution - 0024
    Taipei, 112, Taiwan
  • Local Institution - 0023
    Taoyuan, 333, Taiwan
  • Local Institution - 0011
    London, Greater London SE19RT, United Kingdom
  • Local Institution - 0014
    Manchester, Greater Manchester M20 4BX, United Kingdom
  • Local Institution - 0012
    Glasgow, Lanarkshire G12 0YN, United Kingdom
  • Local Institution - 0015
    Metropolitan Borough of Wirral, Merseyside CH63 4JY, United Kingdom
  • Local Institution - 0013
    Birmingham, West Midlands B15 2TH, United Kingdom
  • Local Institution - 0010
    London, NW3 2QG, United Kingdom
09

References and documents

Publications

  • Zhou X, Cao J, Topatana W, Xie T, Chen T, Hu J, Li S, Juengpanic S, Lu Z, Zhang B, Wang K, Feng X, Shen J, Chen M. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. Immunotherapy. 2023 Apr;15(5):353-365. doi: 10.2217/imt-2022-0168. Epub 2023 Feb 27. PubMed 36852452 ↗
  • Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. J Clin Oncol. 2023 Mar 20;41(9):1747-1757. doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13. PubMed 36512738 ↗
  • Sove RJ, Verma BK, Wang H, Ho WJ, Yarchoan M, Popel AS. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. J Immunother Cancer. 2022 Nov;10(11):e005414. doi: 10.1136/jitc-2022-005414. PubMed 36323435 ↗
  • Kudo M, Matilla A, Santoro A, Melero I, Gracian AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021 Sep;75(3):600-609. doi: 10.1016/j.jhep.2021.04.047. Epub 2021 May 26. PubMed 34051329 ↗
  • Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12. PubMed 33001135 ↗
  • Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020 Dec;73(6):1460-1469. doi: 10.1016/j.jhep.2020.07.026. Epub 2020 Jul 22. PubMed 32710922 ↗
  • Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7. PubMed 31176752 ↗
  • El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20. PubMed 28434648 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Nov 2024, 144 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 144 months is above that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2012
First posted
Aug 7, 2012
StartActual
Oct 30, 2012
Primary completionActual
Nov 12, 2024
CompletionActual
Nov 12, 2024
Results first posted
Dec 24, 2025
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01658878
Responsible party
Sponsor
First posted
Aug 7, 2012
Start date
Oct 30, 2012
Primary completion
Nov 12, 2024
Completion
Nov 12, 2024
Results posted
Dec 24, 2025
Last update
Dec 24, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cabozantinib

Start the discussion